ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1523

The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR

Luis I Lozano-Plata1, David Vega-Morales2, Ana Arana-Guajardo3, Mario Alberto Garza-Elizondo4, Cassandra Skinner-Taylor4, Roberto Negrete-López1, Jorge Esquivel-Valerio5 and Miguel A Villarreal-Alarcón6, 1Servicio de Reumatología, Departamento de Medicina Interna. Hospital Universitario “Dr. José Eleuterio González”. Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Universidad Autónoma de Nuevo Léon, Monterrey, Mexico, 3Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 4Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 5Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, 6Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. Jose Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fibromyalgia and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The disease activity score (DAS) is a method used to monitor disease activity in Rheumatoid Arthritis (RA). Diseases that cause chronic pain or mood disorders have been previously studied to assess their effect on the activity of RA. The aim of the study was to assess clinic, activity, and function characteristics on the DAS28-ESR in RA patients.

Methods:

This is an observational, descriptive cross-sectional study fron march 2013 to march 2014. We included patients with RA according to 2010 ACR/EULAR classification criteria. We analyzed the effect of Fibromyalgia, Knee Osteoarthritis knee, presence of Tendinopathy (any) on the status of RA activity. Evaluation of Health Assessment Questionnaire (HAQ) and Patient Global Visual Analogue Scale (PG-VAS) were included. We considered a VAS> 40 with clinical significance. All patients underwent joint count and ESR.

Results:

We analyzed 395 patients, 360 (91.1%) women , with mean age of 51.1 (SD 12.7). Table 1 shows the clinical and activity characteristics of the patients. We found in the bivariate analysis that the presence of a PG-VAS >40 was associated with a DAS28-ESR greater than 2.6 (OR: 12.47, 5.2-29 95% CI, p = 0.001). Fibromyalgia was a predictor of PG-VAS >40 (OR 3.49, 1.72-7.08 95% CI, p = 0.0001). The rest of the variables analyzed did not influence.

Conclusion:

We observed a negative effect of Fibromyalgia in the PG-VAS and therefore in the DAS28-ESR in patients with RA. The effect size of diagnostic Fibromyalgia on the DAS28 was 27%. We propose to adjust the DAS28, when the PG-VAS is above 40, by multiplying by 0.73, to consider the effect of Fibromyalgia in the evaluation.

Table 1. Clinic, activity, and function characteristics of RA patients

Variables

With FM

n= 39

Without FM

n= 356

p

Age, years mean, SD

55.5, 6.8

50.6, 13.3

0.02

DAS28-ESR median, IQR

3.01, 1.3

3.1, 1.4

0.5

ESR mm/Hr median, IQR

27.02, 14.8

29.1, 12

0.35

PG-VAS mm, mean , SD

29.9, 4.7

22, 1.2

0.001

PG-VAS > 40mm n,%

15, 38.5

54, 15.2

0.001

Presence of morning stiffness n,%

17, 43.6

119, 33.4

0.2

Presence of night pain n,%

39,100

336, 94.4

0.3

Functional class I n,%

32, 82.1

270, 75.8

0.14

Knee Osteoarthritis n,%

11, 28.2

61, 17.1

0.08

Tendinopathy n,%

4, 10.3

15, 4.2

0.094

HAQ-8

– Dress yourself, including tying shoelaces and doing buttons? n,%

29, 74.4

217, 61

0.1

– Get in and out of bed? n,%

36, 92.3

337, 94.7

0.5

– Lift a full cup or glass to your mouth? n,%

36, 92.3

317, 89

0.5

– Wash and dry your entire body? n,%

36, 92.3

336, 94.4

0.5

– Bend down to pick up clothing from the floor? n,%

34, 87.2

326, 91.6

0.35

– Turn faucets/taps on and off? n,%

38, 97.4

342, 96.1

0.67

– Get in and out of a car? n,%

36, 92.3

342, 96.1

0.27

– Walk outdoors on flat ground?

34, 87.2

320, 89.9

0.5

DAS28-ESR: Disease Activity Score of 28 joints with ESR, PG-VAS: Patient Global visual analogue scale, ESR: erythrocyte sedimentation rate, IQR: interquartile range, HAQ: Health Assessment Questionnaire. Functional class I:Without limitation to activities of daily living


Disclosure: L. I. Lozano-Plata, None; D. Vega-Morales, None; A. Arana-Guajardo, None; M. A. Garza-Elizondo, None; C. Skinner-Taylor, None; R. Negrete-López, None; J. Esquivel-Valerio, None; M. A. Villarreal-Alarcón, None.

To cite this abstract in AMA style:

Lozano-Plata LI, Vega-Morales D, Arana-Guajardo A, Garza-Elizondo MA, Skinner-Taylor C, Negrete-López R, Esquivel-Valerio J, Villarreal-Alarcón MA. The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-effect-size-of-fibromyalgia-on-pg-vas-in-rheumatoid-arthritis-patients-adjustment-proposal-in-das28-esr/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-size-of-fibromyalgia-on-pg-vas-in-rheumatoid-arthritis-patients-adjustment-proposal-in-das28-esr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology